‘2019 한국형 조현병 약물치료 지침서’에 따른 조현병에서 동반증상 및 부작용의 치료
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 윤제연 | - |
dc.contributor.author | 이정석 | - |
dc.contributor.author | 강시현 | - |
dc.contributor.author | 남범우 | - |
dc.contributor.author | 이승재 | - |
dc.contributor.author | 이승환 | - |
dc.contributor.author | 최준호 | - |
dc.contributor.author | 김찬형 | - |
dc.contributor.author | 정영철 | - |
dc.date.accessioned | 2022-07-10T14:59:38Z | - |
dc.date.available | 2022-07-10T14:59:38Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 2287-6995 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/148610 | - |
dc.description.abstract | Objectives: The current study covers a secondary revision of the guidelines for the pharmacotherapy of schizophrenia issued by the Korean Medication Algorithm for Schizophrenia (KMAP-SCZ) 2001, specifically for co-existing symptoms and antipsychotics-related side-effects in schizophrenia patients. Methods: An expert consensus regarding the strategies of pharmacotherapy for positive symptoms of schizophrenia, co-existing symptoms of schizophrenia, and side-effect of antipsychotics in patients with schizophrenia was retrieved by responses obtained using a 30-item questionnaire. Results: For the co-existing symptoms, agitation could be treated with oral or intramuscular injection of benzodiazepine or antipsychotics; depressive symptoms with atypical antipsychotics and adjunctive use of antidepressant; obsessive-compulsive symptoms with selective serotonin reuptake inhibitors and antipsychotics other than clozapine and olanzapine; negative symptoms with atypical antipsychotics or antidepressants; higher risk of suicide with clozapine; comorbid substance abuse with use of naltrexone or bupropion/varenicline, respectively. For the antipsychotics-related side effects, anticholinergics (extrapyramidal symptom), propranolol and benzodiazepine (akathisia), topiramate or metformin (weight gain), change of antipsychotics to aripiprazole (hyperprolactinemia and prolonged QTc) or clozapine (tardive dyskinesia) could be used. Conclusion: Updated pharmacotherapy strategies for co-existing symptoms and antipsychotics-related side effects in schizophrenia patients as presented in KMAP-SCZ 2019 could help effective clinical decision making of psychiatrists as a preferable option. | - |
dc.language | 한국어 | - |
dc.language.iso | ko | - |
dc.publisher | 대한조현병학회 | - |
dc.title | ‘2019 한국형 조현병 약물치료 지침서’에 따른 조현병에서 동반증상 및 부작용의 치료 | - |
dc.title.alternative | Korean Treatment Guideline on Pharmacotherapy of Co-existing Symptoms and Antipsychotics-related Side Effects in Patients with Schizophrenia | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 최준호 | - |
dc.identifier.doi | 10.16946/kjsr.2019.22.2.21 | - |
dc.identifier.bibliographicCitation | 대한조현병학회지, v.22, no.2, pp.21 - 33 | - |
dc.relation.isPartOf | 대한조현병학회지 | - |
dc.citation.title | 대한조현병학회지 | - |
dc.citation.volume | 22 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 21 | - |
dc.citation.endPage | 33 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART002519171 | - |
dc.description.journalClass | 2 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | kci | - |
dc.description.journalRegisteredClass | other | - |
dc.subject.keywordAuthor | Antipsychotics-related Side effects | - |
dc.subject.keywordAuthor | Co-existing symptoms | - |
dc.subject.keywordAuthor | Schizophrenia | - |
dc.subject.keywordAuthor | 2019 Korean Medication Algorithm for Schizophrenia | - |
dc.subject.keywordAuthor | 동반증상 | - |
dc.subject.keywordAuthor | 조현병 | - |
dc.subject.keywordAuthor | 항정신병약물 부작용 | - |
dc.subject.keywordAuthor | 2019 한국형 조현병 약물치료 지침서 | - |
dc.identifier.url | https://www.kjsr.org/journal/view.php?doi=10.16946/kjsr.2019.22.2.21 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.